Understanding the differences between formulation variants helps you evaluate what you are actually receiving and how it compares to alternatives
Brand-name oral semaglutide (Rybelsus) is already FDA-approved for diabetes, and an oral formulation for weight loss is expanding access for patients who prefer pills over injections
It may cause side effects of qsymia such as tingling in the hands and feet, dizziness, constipation, dry mouth, and altered taste
NICE guidance (NG28) recommends considering dose reductions of insulin or sulfonylureas when initiating a GLP-1 receptor agonist to mitigate this risk
Its a small step that can have a big impact on public health, helping people manage diabetes and weight loss without breaking the bank
As dozens of novel agents currently under study seek new indications, the question arises of whether the traditional practice of two confirmatory trials for every indication expansion remains justified, especially when database study emulations that benchmark against previously conducted, closely related reference trials have yielded aligned results 33,34
.webp)
